In-utero stem cell treatment for Bart’s hydrops
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy, Women’s health & pregnancy clinical trials.
This trial studies whether giving hematopoietic (blood-forming) stem cells while the baby is still in the womb can treat fetuses with Bart’s hydrops fetalis syndrome. It aims to improve outcomes after prenatal intervention in carefully selected pregnancies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant before 26 weeks and have a confirmed diagnosis of Bart’s hydrops fetalis syndrome (BHFS) from a prenatal test (CVS, amniocentesis, or cordocentesis).
- You and the parents choose to move forward with in-utero treatment and are willing to continue it for the rest of the pregnancy if needed.
- The fetus does not have a second major birth defect (not related to BHFS) that would make outcomes much worse.
- The fetus does not have other major genetic or chromosome problems besides BHFS that would make outcomes much worse.
- Ultrasound or heart (echocardiogram) checks do not show a very high risk that the baby will die after the procedure.
- The pregnancy has not ended in loss (in-utero death) before the treatment happens.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new way to restore working blood-making cells using your own stem cells for people with transfusion-dependent beta thalassemia major. The goal is to improve safety and blood results, and possibly reduce problems from the disease.
This trial tests giving a bone marrow transplant to a fetus diagnosed with Fanconi anemia while still in the womb. The goal is to help the baby's body make healthy blood cells before birth, potentially reducing complications after birth.
This trial tests whether giving stem cells to very premature babies can help prevent bronchopulmonary dysplasia, a lung condition that often affects babies born before 28 weeks. The stem cells are given through an IV, and the study compares them to a placebo to see if they improve lung health.
This trial tests whether infusing special stem cells (from donated bone marrow) into the uterine artery can help thicken the womb lining in women with severe uterine scarring (adhesions) and a history of failed embryo transfers due to thin lining. The goal is to make it possible to successfully implant a frozen embryo and achieve pregnancy.
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
This trial tests a new treatment using stem cells from umbilical cord blood or tissue, given to infants with biliary atresia during their Kasai surgery. The goal is to improve liver function and reduce the need for a liver transplant.
Hear when a new Haemoglobin Barts Hydrops trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.